EasyCheck360® detects Circulating Tumour cells in the blood sample of an individual, indicating a higher risk of the presence of cancer. This is a screening test and not a diagnostic test. It highlights the individuals who require further consultation with a physician and additional imaging tests to confirm the findings. 1

EasyCheck360® is not designed to replace recommended cancer screening methods and should be used alongside them.

A negative test means Circulating Tumour Cells (CTCs) were not detected, indicating lower risk of presence of cancer (carcinoma).

Since EasyCheck360® is a non-invasive blood test, it can be done frequently without any drawbacks. However, it is recommended to have the test once every 12 months.

A positive result indicates that Circulating Tumour Cells were detected, indicating a higher risk of the presence of cancer (carcinoma). Individuals with such findings are advised to undergo a standard of care workup, like imaging in consultation with their physician, to identify if the cancer is present.

No, individuals with suspected or noticeable symptoms of cancer should promptly consult a medical expert for proper evaluation and guidance.

No, it is not intended for this purpose.

Trublood™ utilises a cutting-edge technique known as immunocytochemistry (ICC) staining to detect Circulating Tumour Cells (CTCs) within the bloodstream. CTCs are cancer cells that break away from the primary tumour and enter the bloodstream, potentially aiding disease spread. This approach not only detects these cells but also differentiates distinct subtypes of CTCs by identifying specific molecular markers, providing critical insights into the cancer's characteristics and potential progression.

Trublood™ detects carcinomas, which are cancers that start in cells lining the organs and body surfaces, like the skin, lungs, and colon. It does not detect blood or lymphatic cancer.

Yes, Trublood™ can often differentiate between cancers originating in glandular cells (like adenocarcinoma) and those in the skin or lining of the lungs (like squamous cell carcinoma).

Trublood™ can identify common cancer types, such as adenocarcinoma, squamous cell carcinoma, and neuroendocrine tumours, but may not detect some rare subtypes.

Trublood™ identifies the type of epithelial cancer but does not provide information on the tumour's grade or aggressiveness.

Trublood™ is a qualitative test designed for detecting carcinoma in patients with signs or symptoms of cancer. It is not a quantitative test for monitoring by counting CTCs.

Yes, Trublood™ has been tested in both early-stage and advanced cancers, with an overall accuracy of 94.6%.

Trublood™ is not a biochemistry test to detect protein cancer markers; it is a screening test designed for detecting cancer in patients with specific symptoms or organ-related signs.

Trublood™ is validated for cases with a specific organ suspicion, not for non-specific symptoms like weight loss without a particular organ focus.

A blood sample is taken from a vein, like routine blood tests, but with specific storage and transport requirements.

It is transported in temperature-controlled packaging.

Consult with your doctor for further evaluations.

Trublood™ is a highly specific test, but a biopsy may still be recommended based on your doctor’s advice.

You can repeat the test in a month and consult with your doctor.

Yes, doctors use Trublood™ for the detection of organ-specific cancer cases, especially if a biopsy is challenging.

No, Trublood™ is validated only for adults, 18 years and older.

Trublood™ is a non-invasive blood test that can detect the presence of cancer and its type without requiring a tissue biopsy.

Trublood™ cannot detect certain types of cancer like blood cancers, lymphatic cancers, or some rare carcinomas.

Your doctor may consider Trublood™ results but will factor in other test results as well.

Exacta™ is a detailed analysis that looks at a patient's sample (like tissue, blood, or fluids) to find the best treatment options. It examines DNA, RNA, drug effectiveness, and drug pathways to recommend personalised drug combinations that would most likely work. Treatments are given under the care of your oncologist.

Cancer can grow and change quickly, making it harder to treat. Starting treatment immediately helps prevent cancer from becoming resistant to therapies, which may otherwise require a new analysis.

The recommendations will only include FDA-approved drugs for cancer or non-cancer conditions. Investigational or experimental drugs will not be included.

Yes, liquid biopsy allows frequent monitoring of the cancer's status and response to treatment. It can detect signs of recurrence or resistance and help your doctor adjust your treatment plan to improve the quality of life and survival.

Pinaka™ is a qualitative test. It gives a simple result, positive or negative, based on whether certain markers are expressed on the circulating tumour cells or not.

A 'negative' result means the cancer cells do not show the specific marker being tested.

Pinaka™ is designed to test specific markers based on the approved indications for each type of cancer (e.g., ER, PR, HER2, PDL1, etc.).

Since Pinaka™ is a non-invasive blood test, it can be done multiple times over a period to track your progress. Your doctor will decide if and when repeat testing is needed, based on your individual condition and treatment response.

Pinaka™ is designed to identify patients who are more likely to benefit from targeted therapies, just like traditional tumour tissue testing. However, your response to treatment depends on various factors, including your health, the specific cancer type, and your immune system.

Pinaka™ is not designed for monitoring cancer recurrence.

Chemoscale™ is a test conducted on live tumour cells to see which drugs or combinations would work more effectively for a cancer patient. This approach avoids the 'trial and error' method, helping patients and doctors make informed treatment decisions based on actual evidence.

Chemoscale™ is beneficial for newly diagnosed patients in choosing the best chemotherapy, for patients with recurring cancer, and for those with solid tumours.

Not all drugs work the same for everyone. Chemoscale™ shows which treatments are likely to be effective before starting, saving time and resources.

While most tests focus on targeted therapies, Chemoscale™ specifically tests how a patient's cancer cells respond to chemotherapy drugs, allowing for accurate and personalised treatment recommendations.

Chemoscale™ is suitable for most cancer patients for whom chemotherapy is a treatment option.

Results are available within 12-14 working days after the sample is received.

Cancer cells change quickly, gaining advantages that help them survive and grow. Cancertrack™ monitors these changes in real-time, identifying signs of recurrence, resistance to treatment, or new weaknesses. This information helps doctors adjust treatments promptly.

Cancertrack™ is best used at key milestones in cancer treatment, especially during follow-up when imaging shows that the tumour has disappeared, to monitor for recurrence.

Although Cancertrack™ is thorough, individual biological factors can sometimes affect results. However, this impact is usually minimised through repeated testing.